Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice

Ankit Jain*, Shivakumar Chitturi, Geoffrey Peters, Desmond Yip

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    10 Citations (Scopus)

    Abstract

    Hepatocellular carcinoma (HCC) is the most common primary liver cancer. For advanced HCC, sorafenib was considered the standard of care for more than ten years. Recently the atezolizumab and bevacizumab combination has become standard of care for these patients without contraindications to either immune checkpoint inhibitors or antiangiogenic therapy. We now review the practical aspects of the atezolizumab and bevacizumab combination, including current evidence, indications, contraindications, management of adverse events, sequencing of this combination, areas of current knowledge gaps and future areas of active clinical research of this combination for busy clinicians in clinical practice.

    Original languageEnglish
    Pages (from-to)1132-1142
    Number of pages11
    JournalWorld Journal of Hepatology
    Volume13
    Issue number9
    DOIs
    Publication statusPublished - 2021

    Fingerprint

    Dive into the research topics of 'Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice'. Together they form a unique fingerprint.

    Cite this